|
1
|
LeVasseur N, Clemons M, Hutton B, Shorr R
and Jacobs C: Bone-targeted therapy use in patients with bone
metastases from lung cancer: A systematic review of randomized
controlled trials. Cancer Treat Rev. 50:183–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lazzari C, Bulotta A, Ducceschi M, Viganò
MG, Brioschi E, Corti F, Gianni L and Gregorc V: Historical
evolution of second-line therapy in non-small cell lung cancer.
Front Med (Lausanne). 4:42017.PubMed/NCBI
|
|
3
|
Socinski MA: Update on taxanes in the
first-line treatment of advanced non-small-cell lung cancer. Curr
Oncol. 21:e691–e703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kenmotsu H and Tanigawara Y:
Pharmacokinetics, dynamics and toxicity of docetaxel: Why the
japanese dose differs from the western dose. Cancer Sci.
106:497–504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kan C, Vargas G, Pape FL and Clézardin P:
Cancer cell colonisation in the bone microenvironment. Int J Mol
Sci. 17:E16742016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Popper HH: Progression and metastasis of
lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stafford JH and Thorpe PE: Increased
exposure of phosphatidylethanolamine on the surface of tumor
vascular endothelium. Neoplasia. 13:299–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fahrmann JF, Grapov D, Defelice BC, Taylor
S, Kim K, Kelly K, Wikoff WR, Pass H, Rom WN, Fiehn O and Miyamoto
S: Serum phosphatidylethanolamine levels distinguish benign from
malignant solitary pulmonary nodules and represent a potential
diagnostic biomarker for lung cancer. Cancer Biomark. 16:609–617.
2016.PubMed/NCBI
|
|
9
|
Li S, Qin J, Tian C, Cao J, Fida G, Wang
Z, Chen H, Qian Z, Chen WR and Gu Y: The targeting mechanism of DHA
ligand and its conjugate with gemcitabine for the enhanced tumor
therapy. Oncotarget. 5:3622–3635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Riediger ND, Othman RA, Suh M and
Moghadasian MH: A systemic review of the roles of n-3 fatty acids
in health and disease. J Am Diet Assoc. 109:668–679. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rahman MM, Veigas JM, Williams PJ and
Fernands G: DHA is a more potent inhibitor of breast cancer
metastasis to bone and related osteolysis than EPA. Breast Cancer
Res Treat. 141:341–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murphy RA, Mourtzakis M, Chu QS, Baracos
VE, Reiman T and Mazurak VC: Supplementation with fish oil
increases first-line chemotherapy efficacy in patients with
advanced nonsmall cell lung cancer. Cancer. 117:3774–3780. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sánchez-Lara K, Turcott JG,
Juárez-Hernández E, Nuñez-Valencia C, Villanueva G, Guevara P, De
la Torre-Vallejo M, Mohar A and Arrieta O: Effects of an oral
nutritional supplement containing eicosapentaenoic acid on
nutritional and clinical outcomes in patients with advanced
non-small cell lung cancer: Randomised trial. Clin Nutr.
33:1017–1023. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo
X, Xia X, Volk DE, Lokesh GL, Thiviyanathan V, et al: Bone marrow
endothelium-targeted therapeutics for metastatic breast cancer. J
Control Release. 187:22–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yates CM, Tull SP, Madden J, Calder PC,
Grimble RF, Nash GB and Rainger GE: Docosahexaenoic acid inhibits
the adhesion of flowing neutrophils to cytokine stimulated human
umbilical vein endothelial cells. J Nutr. 141:1331–1334. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chauvin L, Goupille C, Blanc C, Pinault M,
Domingo I, Guimaraes C, Bougnoux P, Chevalier S and Mahéo K: Long
chain n-3 polyunsaturated fatty acids increase the efficacy of
docetaxel in mammary cancer cells by downregulating Akt and
PKCε/δ-induced ERK pathways. Biochim Biophys Acta. 1861:380–390.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zu Y, Hu Y, Yu X and Jiang S:
Docetaxel-loaded bovine serum albumin nanoparticles conjugated
docosahexaenoic acid for inhibiting lung cancer metastasis to bone.
Anticancer Agents Med Chem. 17:542–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang S, Gong X, Zhao X and Zu Y:
Preparation, characterization, and antitumor activities of
folate-decorated docetaxel-loaded human serum albumin
nanoparticles. Drug Deliv. 22:206–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bölükbas DA and Meiners S: Lung cancer
nanomedicine: Potentials and pitfalls. Nanomedicine (Lond).
10:3203–3212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bedikian AY, DeConti RC, Conry R, Aqarwata
S, Papadopoulos N, Kim KB and Ernstoff M: Phase 3 study of
docosahexaenoic acid-paclitaxel versus dacarbazine in patients with
metastatic malignant melanoma. Ann Oncol. 22:787–793. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Payne M, Ellis P, Dunlop D, Ranson M,
Danson S, Schacter L and Talbot D: DHA-paclitaxel (Taxoprexin) as
first-line treatment in patients with stage IIIB or IV non-small
cell lung cancer: Report of a phase ii open-label multicenter
trial. J Thorac Oncol. 1:984–990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jones RJ, Hawkins RE, Eatock MM, Ferry DR,
Eskens FA, Wilke H and Evans TR: A phase II open-label study of
DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in
previously untreated patients with locally advanced or metastatic
gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol.
61:435–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harries M, O'Donnell A, Scurr M, Reade S,
Cole C, Judson I, Greystoke A, Twelves C and Kaye S: Phase I/II
study of DHA-paclitaxel in combination with carboplatin in patients
with advanced malignant solid tumours. Br J Cancer. 91:1651–1655.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bradley MO, Webb NL, Anthony FH, Devanesan
P, Witman PA, Hemamalini S, Chander MC, Baker SD, He L, Horwitz SB
and Swindell CS: Tumor targeting by covalent conjugation of a
natural fatty acid to paclitaxel. Clin Cancer Res. 7:3229–3238.
2001.PubMed/NCBI
|
|
25
|
Sparreboom A, Wolff AC, Verweij J,
Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC
and Baker SD: Disposition of docosahexaenoic acid-paclitaxel, a
novel taxane, in blood: In vitro and clinical pharmacokinetic
studies. Clin Cancer Res. 9:151–159. 2003.PubMed/NCBI
|
|
26
|
Chu J and Ding J: Plumbagin prevents bone
metastasis of lung adenocarcinoma cell line PC9 by inhibiting
migration and osteolysis. Med Innovation China. 11:11–13. 2014.(In
Chinese).
|
|
27
|
Liu F, Feng L, Zhang L, Zhang X and Zhang
N: Synthesis, characterization and antitumor evaluation of CMCS-DTX
conjugates as novel delivery platform for docetaxel. Int J Pharm.
451:41–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoang B, Ernsting MJ, Tang WS, Bteich J,
Undzys E, Kiyota T and Li SD: Cabazitaxel-conjugated nanoparticles
for docetaxel-resistant and bone metastatic prostate cancer. Cancer
Lett. 410:169–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yared JA and Tkaczuk KH: Update on taxane
development: New analogs and new formulations. Drug Des Devel Ther.
6:371–384. 2012.PubMed/NCBI
|
|
30
|
Ray A, Larson N, Pike DB, Grüner M, Naik
S, Bauer H, Malugin A, Greish K and Ghandehari H: Comparison of
active and passive targeting of docetaxel for prostate cancer
therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm. 8:1090–1099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gligorov J and Lotz JP: Preclinical
pharmacology of the taxanes: Implications of the differences.
Oncologist. 9 Suppl 2:S3–S8. 2004. View Article : Google Scholar
|
|
32
|
Roato I: Bone metastases: When and how
lung cancer interacts with bone. World J Clin Oncol. 5:149–155.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo Q, Xu Z, Wang L, Ruan M and Jin G:
Progress in the research on the mechanism of bone metastasis in
lung cancer. Mol Clin Oncol. 5:227–235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Siddiqui RA, Harvey KA, Xu Z, Bammerlin
EM, Walker C and Altenburg JD: Docosahexaenoic acid: A natural
powerful adjuvant that improves efficacy for anticancer treatment
with no adverse effects. Biofactors. 37:399–412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Merendino N, Costantini L, Manzi L,
Molinari R, D'Eliseo D and Velotti F: Dietary ω-3 polyunsaturated
fatty acid DHA: A potential adjuvant in the treatment of cancer.
Biomed Res Int. 2013:3101862013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vicent S, Perurena N, Govindan R and
Lecanda F: Bone metastases in lung cancer. Potential novel
approaches to therapy. Am J Respir Crit Care Med. 192:799–809.
2015. View Article : Google Scholar : PubMed/NCBI
|
